系统性硬化症相关间质性肺病患者后续进展风险的预测:一项多中心观察性队列研究
该多中心观察性队列研究纳入231例系统性硬化症相关间质性肺病患者,评估已观察到的间质性肺病进展是否预测后续进展。结果显示,以用力肺活量下降≥5%定义的进展并未增加后续进展风险(OR 0·28),但该进展与死亡率升高相关(HR 1·66)。
要点
- 以用力肺活量下降≥5%定义的进展降低后续进展风险(OR 0·28)。
- 用力肺活量下降≥5%与死亡率升高相关(HR 1·66)。
- 其他进展定义均未显示与后续进展相关。
核心结论
- 系统性硬化症相关间质性肺病进展在下一年的年度随访中并不预测进一步的间质性肺病进展,即使在富集人群中也是如此,但进展与死亡率相关。
研究设计与样本
- 多中心观察性队列研究,基于前瞻性收集的数据分析,纳入年龄≥18岁、符合2013年美国风湿病学会-欧洲抗风湿病联盟系统性硬化症分类标准的系统性硬化症相关间质性肺病患者。
- 主要队列于2001年1月至2019年12月诊断,在挪威奥斯陆大学医院风湿科和瑞士苏黎世大学医院风湿科每年随访一次,持续4年。
- 在富集队列中验证发现,该队列包括主要队列中病程短于3年的系统性硬化症相关间质性肺病患者以及2003年1月至2019年9月在美国密歇根大学安娜堡分校风湿科诊断的患者。
主要发现
- 主要队列231例患者中,71例(31%)在访视1至访视2之间出现用力肺活量下降≥5%定义的进展,38例(16%)出现用力肺活量下降≥10%定义的进展,39例(17%)出现进行性肺纤维化定义的进展,89例(39%)出现进行性纤维化性间质性肺病定义的进展。
- 在多变量逻辑回归分析中,调整进展性系统性硬化症相关间质性肺病危险因素和免疫抑制治疗后,访视1至访视2用力肺活量下降≥5%定义的间质性肺病进展降低访视2至访视3进一步进展的风险(OR 0·28 [95%CI 0·12-0·63];p=0·002)。
- 其他定义均未显示后续进展风险:用力肺活量下降≥10%(OR 0·57 [95%CI 0·16-1·99];p=0·38)、进行性肺纤维化(OR 0·93 [95%CI 0·39-2·22];p=0·88)、进行性纤维化性间质性肺病(OR 0·69 [95%CI 0·35-1·36];p=0·28)。
- 在富集队列中,121例患者中41例(34%)出现用力肺活量下降≥5%定义的进展(OR 0·22 [95%CI 0·06-0·87];p=0·031)。
- 用力肺活量下降≥5%与死亡率显著相关(HR 1·66 [95%CI 1·05-2·62];p=0·030),调整其他危险因素后。
关键数值与推荐
- 主要进展定义:用力肺活量下降≥5%。
- 次要进展定义:用力肺活量下降≥10%、进行性肺纤维化、进行性纤维化性间质性肺病。
- 在每次年度访视(访视1之后)应用这些定义。
临床怎么用
- 作者认为,这些结果对临床实践有启示,支持治疗策略的范式转变,主张对存在进展风险的患者启动治疗。
局限性
- 需要进一步研究来确认这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In patients with systemic sclerosis, it is common practice to treat interstitial lung disease (ILD) in patients in whom progression has already occurred. We sought to clarify whether observed progression of systemic sclerosis-associated ILD confers risk for subsequent progression. METHODS: In this multicentre observational cohort study, based on an analysis of prospectively collected data, we included patients with systemic sclerosis-associated ILD aged 18 years or older at diagnosis, who fulfilled the 2013 American College of Rheumatology-European Association of Alliances in Rheumatology systemic sclerosis classification criteria. The main cohort (diagnosed between January 2001 and December 2019) was consecutively followed up annually over 4 years at the Department of Rheumatology at the Oslo University Hospital, Norway, and the Department of Rheumatology at the University Hospital Zurich, Switzerland. We applied four definitions of ILD progression: the primary definition was forced vital capacity (FVC) decline of 5% or more, and secondary definitions included FVC decline of 10% or more, progressive pulmonary fibrosis (PPF), and progressive fibrosing ILD (PF-ILD). We applied these definitions at each annual visit after the first (visit 1). We validated our findings in an enriched cohort that included patients from the main cohort with systemic sclerosis-associated ILD and short disease duration of less than 3 years along with patients diagnosed between January 2003 and September 2019 from the Division of Rheumatology, University of Michigan, Ann Arbor, MI, USA. Multivariable logistic regression analyses were applied to predict ILD progression and its effect on mortality. There was no involvement of people with lived experience in this study. FINDINGS: Of 231 patients with systemic sclerosis-associated ILD from the main cohort (mean age 48·0 years [SD 14·6], 176 [76%] female and 55 [24%] male), 71 (31%) had ILD progression as defined by an FVC decline of 5% or more between visit 1 and visit 2, 38 (16%) as defined by an FVC decline of 10% or more, 39 (17%) as defined by PPF, and 89 (39%) defined by PF-ILD. In multivariable logistic regression analyses, adjusted for risk factors for progressive systemic sclerosis-associated ILD and immunosuppressive treatment, we found that ILD progression, defined by FVC decline of 5% or more, from visit 1 to visit 2 reduced the risk for further progression from visit 2 to visit 3 (odds ratio [OR] 0·28 [95% CI 0·12-0·63]; p=0·002) and that there was no risk for subsequent progression using the other definitions (FVC decline of ≥10%: 0·57 [0·16-1·99; p=0·38]; PPF: 0·93 [0·39-2·22; p=0·88]; and PF-ILD: 0·69 [0·35-1·36]; p=0·28]). Using the primary definition of progression, we found the same results in the enriched systemic sclerosis-associated ILD cohort, wherein 41 (34%) of 121 patients had progression defined by an FVC decline of 5% or more (OR 0·22 [95% CI 0·06-0·87]; p=0·031). FVC decline of 5% or more was significantly associated with mortality (hazard ratio 1·66 [95% CI 1·05-2·62]; p=0·030) adjusted for other risk factors. INTERPRETATION: Systemic sclerosis-associated ILD progression does not predict further ILD progression at the next annual follow-up visit, even in an enriched population, but progression was associated with mortality. These results have implications for clinical practice because they support a paradigm shift in treatment strategy, advocating for initiating therapy in patients at risk of progression. Further research is needed to confirm these findings. FUNDING: None. TRANSLATIONS: For the German and Norwegian translations of the abstract see Supplementary Materials section.
引用
- Hoffmann-Vold AM, Petelytska L, Fretheim H, et al. Predicting the risk of subsequent progression in patients with systemic sclerosis-associated interstitial lung disease with progression: a multicentre observational cohort study. Lancet Rheumatol. 2025. PMID: 40381640. doi:10.1016/S2665-9913(25)00026-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。